Richette P, Latourte A, , et al. - This study was undertaken to assess the effectiveness of tocilizumab, an antibody against the IL-6 receptor, in patients with hand osteoarthritis. Researchers conducted a multicentre, 12-week, randomized, double-blind, placebo-controlled study between November 2015 and October 2018. Changed in visual analogue scale pain at week 6 was the primary outcome. The number of painful and swollen joints, duration of morning stiffness, patients’ and physicians’ global assessment, and function scores were the secondary outcomes. A total of 104 patients were included in the study. In comparison with placebo, tocilizumab was no more effective for pain relief in patients with hand osteoarthritis.